FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Otsuka Reports Interim Data on Sibeprenlimab

[ Price : $8.95]

Otsuka reports positive topline interim data from an ongoing Phase 3 clinical trial of sibeprenlimab and its use for treating immu...

Acromegaly NDA Hit with Complete Response Letter

[ Price : $8.95]

FDA sends Camurus a complete response letter on its NDA for CAM2029 (octreotide) extended-release injection and its use in treatin...

Comments Extended for Chemical Analysis Device Guide

[ Price : $8.95]

Federal Register notice: FDA extends the comment period for a 9/20 notice on a draft guidance entitled Chemical Analysis for Bioco...

Drug Interaction Labeling Guidance

[ Price : $8.95]

FDA publishes a draft guidance with recommendations for the placement and content of drug interaction information in labeling for ...

Sangamo to Seek Accelerated OK on Gene Therapy

[ Price : $8.95]

Sangamo Therapeutics reaches an agreement with FDA on a clear regulatory pathway to accelerated approval for the companys gene the...

Its Official: Tarver Takes on CDRH Director Post

[ Price : $8.95]

FDA names CDRH deputy director Michelle Tarver as the new Center director, replacing retiring head Jeff Shuren, who hand-picked hi...

New FDA Data Tool on Parkinsons

[ Price : $8.95]

FDA says a new open-access dataset on gait patterns in patients with Parkinsons disease may lead to novel medical devices.

3 Stakeholders Nix Biosimilar PSGs

[ Price : $8.95]

Three stakeholders tell FDA they oppose the idea of the agency developing product-specific guidances to promote biosimilar develop...

Digital Health Advisory Committee AI Meeting Materials

[ Price : $8.95]

FDA posts an executive summary and questions for discussion at a scheduled 11/20-21 meeting of its Digital Health Advisory Committ...

Lenz Therapeutics NDA Accepted for Farsightedness

[ Price : $8.95]

FDA accepts for review a Lenz Therapeutics NDA for LNZ100 (aceclidine), an eyedrop medication for treating presbyopia.